TKTsugiyasu Kanda

Tsugiyasu Kanda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tsugiyasu Kanda has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Isao Kobayashi

    Department of Laboratory Medicine, Gunma University School of Medicine

    5 shared publications
  • Ken-Ichi Sekiguchi

    Second Department of Internal Medicine, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, 371, Japan

    2 shared publications
  • Ryozo Nagai

    Second Department of Internal Medicine, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, 371, Japan

    2 shared publications
  • Yukihiro Seta

    Second Department of Internal Medicine, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, 371, Japan

    2 shared publications
  • Bruce M. McManus

    Department of Pathology and Laboratory Medicine, University of British Columbia, St. Paul's Hospital, 2211 Westbrook Mall, Vancouver, BC, V6T2B5, Canada

    1 shared publication
  • DeCheng Yang

    Department of Pathology and Laboratory Medicine, University of British Columbia, St. Paul's Hospital, 2211 Westbrook Mall, Vancouver, BC, V6T2B5, Canada

    1 shared publication

Latest Publications

  • Evaluation of Signal-Averaged Electrocardiography for Clinical Diagnosis in Arrhythmogenic Right Ventricular Dysplasia.

    by Keiko Sekiguchi, Yoshiki Miya, Yoshiaki Kaneko, Tsugiyasu Kanda, Yukihito Fukumura, Nobuo Kotajima, Junichi Tamura, Isao Kobayashi

    Arrhythmogenic right ventricular dysplasia (ARVD) is a heart muscle disorder of unknown etiology that is characterized pathologically by fibrofatty replacement of the right ventricular myocardium. We investigated the relationship between the electrocardiogram (ECG) appearances and signal-averaged ECG (SAECG) in 7 cases with ARVD, and evaluated the usefulness of SAECG as a screening test to detect patients with ARVD. Compared with the conventional 12-lead ECG, the SAECG detects abnormalities at a higher rate in ARVD patients (57% versus 86%). SAECG was more sensitive as a screening test to detect patients with ARVD than 12-lead ECG.


  • Effect of Interleukin-18 on Viral Myocarditis: Enhancement of Interferon- γ and Natural Killer Cell Activity

    by Tsugiyasu Kanda, Toru Tanaka, Ken-Ichi Sekiguchi, Yukihiro Seta, Masashi Kurimoto, Janet E. Wilson McManus, Ryozo Nagai, DeCheng Yang, Bruce M. McManus, Isao Kobayashi


  • Antipituitary Antibodies as Pathogenetic Factors in Patients with Pituitary Disorders.

    by Takashi Kikuchi, Shigeki Yabe, Tsugiyasu Kanda, Isao Kobayashi

    Our previous reports showed detection of antipituitary antibodies (APA) by immunoblot analysis and enzyme linked immunosorbent assay (ELISA) by using rat pituitary tissue as antigen in patients with certain endocrine disorders. In the present report, we evaluated APA by using our immunoblot and ELISA technique in 76 patients with various pituitary disorders. The prevalence of a 22kDa band of APA detected by immunoblot was found to be significantly higher (P<0.01) in patients with pituitary disorders (20 of 76, 26% than in the controls (3 of 209, 1%). APA levels detected by ELISA were significantly higher in patients with GH deficiency, isolated ACTH deficiency, acromegaly, and idiopathic panhypopituitarism compared with control (mean±SD; 2.40±2.66, 2.36±1.87), 2.09±1.87, 3.10±1.96 versus 1.42±0.64 (C.I.) P<0.05, respectively). APA levels detected by ELISA in 7 patients with GH deficiency showed a statistically significant decrease (p<0.05) after administration of GH replacement therapy. APA detection by immunoblot is useful in examining as pathogenesis, while ELISA may be useful as an objective index of pathological state in patients with autoimmune-related pituitary disorders.


  • Therapy with the Nonpeptide Endothelin Receptor Antagonist 97-139 in a Murine Model of Congestive Heart Failure. Reduction of Cardiac Mass and Myofiber Hypertrophy.

    by Yukihiro Seta, Tsugiyasu Kanda, Tomoyoshi Yokoyama, Masashi Arai, Ken-Ichi Sekiguchi, Tohru Tanaka, Isao Kobayashi, Ryozo Nagai

    Endothelin-1 (ET-1) is a potent vasoconstrictor. This peptide exerts numerous effects on the heart, including regulation of cardiomyocyte growth during hypertrophy. The effects of the structurally novel, nonpeptide, ET-1-selective, competitive antagonist (ETA) 97-139 were investigated in mice with congestive heart failure (CHF) and myocardial hypertrophy. Morphological and microscopical analyses were conducted on day 56 after viral inoculation following 28 day treatment with 99-139. Eight week-old DBA2 mice were intraperitoneally inoculated with encephalomyocarditis virus at a dose of 500 pfu/mouse. The 30 mice were divided into two groups--an ETA treated group and an untreated group. Heart weight (HW) in the infected group was significantly (p < 0.05) increased compared to that in the uninfected group. HW and the HW/body weight (BW) ratio were significantly (p < 0.05) reduced in the ETA treated group compared with the untreated group (HW; 127.7 +/- 6.2 mg vs 144.3 +/- 4.2 mg, HW/BW; 4.9 +/- 0.9 x 10(-3) vs 5.4 +/- 0.5 x 10(-3)). Myofiber diameter in the ETA treated group was significantly reduced compared with the untreated group (12.1 +/- 1.5 microm vs 14.3 +/- 1.9 microm). These results suggest the ET-1 receptor antagonist 97-139 has an effect on the reduction of cardiac mass and myofiber hypertrophy, and that 97-139 may be a useful agent for CHF due to viral myocarditis.


  • Comparative Effects of Losartan, Captopril, and Enalapril on Murine Acute Myocarditis Due to Encephalomyocarditis Virus

    by Minoru Araki, Tsugiyasu Kanda, Susumu Imai, Tadashi Suzuki, Kazuhiko Murata, Isao Kobayashi

    Losartan, a recently developed nonpeptide angiotensin II (AII) receptor antagonist, was orally administered for 14 days to mice with viral myocarditis, beginning 7 days after encephalomyocarditis virus inoculation. The angiotensin-converting enzyme inhibitors (ACEI) captopril and enalapril were also administered in the same manner to compare the therapeutic effects of these three drugs on the degree of myocarditis, acute heart failure, and left ventricular (LV) hypertrophy. Heart weight and the heart weight/body weight ratio were reduced by losartan (60 mg/kg/day) and captopril (7.5 mg/ kg/day), but not by enalapril (1 mg/kg/day). LV wall thickness and cavity dimension were decreased in the losartan and captopril groups. Captopril reduced both myocardial necrosis and inflammation, whereas enalapril reduced myocardial necrosis but not inflammation. However, none of the studied losartan doses (1.2, 12, 60 mg/ kg/day) influenced myocardial necrosis and inflammation resulting from viral infection. Thus, specific blockade of AII is beneficial in congestive heart failure (CHF) and LV hypertrophy but is not effective in viral-evoked inflammation and injury.